Published online Aug 26, 2022. doi: 10.12998/wjcc.v10.i24.8535
Peer-review started: March 23, 2022
First decision: May 30, 2022
Revised: June 9, 2022
Accepted: July 16, 2022
Article in press: July 16, 2022
Published online: August 26, 2022
Post-transarterial chemoembolization (TACE) liver failure occurs frequently in hepatocellular carcinoma (HCC) patients received TACE procedure.
Identification of risk factors for post-TACE liver failure is important for TACE treatment decision-making.
The aim of this retrospective study was to assess the occurrence rate and predictive factors of post-TACE liver failure in HCC patients.
Baseline characteristics and laboratory parameters of HCC patients received TACE therapy were assessed.
A total of 35.2% (70/199) HCC patients occurred post-TACE liver failure after TACE therapy. Logistic models indicated that microspheres plus gelatin embolization and main tumor size > 5 cm were risk predictors for the occurrence of post-TACE liver failure. Conversely, HCC patients who underwent tumor resection surgery before the TACE procedure had a lower risk for post-TACE liver failure.
Microspheres plus gelatin embolization and main tumor size might be risk factors for the occurrence of post-TACE liver failure in HCC patients, while tumor resection history could be a favorable factor for post-TACE liver failure.
Pre-TACE assessment including embolization strategy, tumor size, and hepatic functional reserve is of great importance for avoiding post-TACE liver failure. More studies need to be done to confirm these findings.